208 related articles for article (PubMed ID: 23972551)
1. Complications of chemotherapy, a basic science update.
Mazevet M; Moulin M; Llach-Martinez A; Chargari C; Deutsch E; Gomez AM; Morel E
Presse Med; 2013 Sep; 42(9 Pt 2):e352-61. PubMed ID: 23972551
[TBL] [Abstract][Full Text] [Related]
2. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
3. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.
Koleini N; Kardami E
Oncotarget; 2017 Jul; 8(28):46663-46680. PubMed ID: 28445146
[TBL] [Abstract][Full Text] [Related]
4. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
[TBL] [Abstract][Full Text] [Related]
5. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
[TBL] [Abstract][Full Text] [Related]
6. The beneficial role of exercise in mitigating doxorubicin-induced Mitochondrionopathy.
Marques-Aleixo I; Santos-Alves E; Oliveira PJ; Moreira PI; Magalhães J; Ascensão A
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):189-199. PubMed ID: 29408395
[TBL] [Abstract][Full Text] [Related]
7. Cardiomyocyte death in doxorubicin-induced cardiotoxicity.
Zhang YW; Shi J; Li YJ; Wei L
Arch Immunol Ther Exp (Warsz); 2009; 57(6):435-45. PubMed ID: 19866340
[TBL] [Abstract][Full Text] [Related]
8. Exercise as a beneficial adjunct therapy during Doxorubicin treatment--role of mitochondria in cardioprotection.
Ascensão A; Oliveira PJ; Magalhães J
Int J Cardiol; 2012 Apr; 156(1):4-10. PubMed ID: 21636148
[TBL] [Abstract][Full Text] [Related]
9. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
10. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
11. Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring.
Wenningmann N; Knapp M; Ande A; Vaidya TR; Ait-Oudhia S
Mol Pharmacol; 2019 Aug; 96(2):219-232. PubMed ID: 31164387
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway.
Danz ED; Skramsted J; Henry N; Bennett JA; Keller RS
Free Radic Biol Med; 2009 Jun; 46(12):1589-97. PubMed ID: 19303434
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches.
Sheibani M; Azizi Y; Shayan M; Nezamoleslami S; Eslami F; Farjoo MH; Dehpour AR
Cardiovasc Toxicol; 2022 Apr; 22(4):292-310. PubMed ID: 35061218
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin.
Govender J; Loos B; Marais E; Engelbrecht AM
J Pineal Res; 2014 Nov; 57(4):367-80. PubMed ID: 25230823
[TBL] [Abstract][Full Text] [Related]
15. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
[TBL] [Abstract][Full Text] [Related]
16. DNA damage is an early event in doxorubicin-induced cardiac myocyte death.
L'Ecuyer T; Sanjeev S; Thomas R; Novak R; Das L; Campbell W; Heide RV
Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H1273-80. PubMed ID: 16565313
[TBL] [Abstract][Full Text] [Related]
17. Physical exercise prior and during treatment reduces sub-chronic doxorubicin-induced mitochondrial toxicity and oxidative stress.
Marques-Aleixo I; Santos-Alves E; Mariani D; Rizo-Roca D; Padrão AI; Rocha-Rodrigues S; Viscor G; Torrella JR; Ferreira R; Oliveira PJ; Magalhães J; Ascensão A
Mitochondrion; 2015 Jan; 20():22-33. PubMed ID: 25446396
[TBL] [Abstract][Full Text] [Related]
18. A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity.
de Oliveira BL; Niederer S
PLoS Comput Biol; 2016 Nov; 12(11):e1005214. PubMed ID: 27870850
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
Octavia Y; Tocchetti CG; Gabrielson KL; Janssens S; Crijns HJ; Moens AL
J Mol Cell Cardiol; 2012 Jun; 52(6):1213-25. PubMed ID: 22465037
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying the protective effect of eugenol in rats with acute doxorubicin cardiotoxicity.
Fouad AA; Yacoubi MT
Arch Pharm Res; 2011 May; 34(5):821-8. PubMed ID: 21656368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
